05/10/22 6:30 AMNasdaq : VERV earningsclinical trialVerve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial ResultsVerve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States Regulatory Filings for VERVE-101 in Second Half of 2022 Cash, Cash Equivalents and MarketableRHEA-AIneutral
05/09/22 6:30 AMNasdaq : VERV Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022VERVE-101 Preclinical Data Package Supports Company’s Global Development Strategy and Regulatory Submissions for Clinical Trials in Patients with HeFH Single Intravenous Infusion of VERVE-101 Clinical Formulation Led to Mean 68% Reduction in Plasma LDL-C in NHPs Out to One-Year with GoodRHEA-AIvery positive
05/04/22 6:30 AMNasdaq : VERV conferencesVerve Therapeutics to Participate in Upcoming May Investor ConferencesVerve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participateRHEA-AIneutral
04/26/22 6:30 AMNasdaq : VERV Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone SymposiaExtensive Analyses in Multiple Human Cell Types Demonstrate Minimal to No Off-target Editing Following VERVE-101 Treatment, Supporting its Planned Clinical Initiation in 2022 Whole Genome Sequencing at 500X Coverage of Primary Human Liver Cells Treated with VERVE-101 Demonstrated No IncreasedRHEA-AIneutral
04/04/22 6:30 AMNasdaq : VERV Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease VerveRHEA-AIneutral
03/24/22 6:30 AMNasdaq : VERV conferencesVerve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease ConferenceVerve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Andrew Bellinger, M.D., Ph.D., chief scientific officer and chiefRHEA-AIneutral
03/14/22 6:30 AMNasdaq : VERV earningsVerve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results Significant Progress Anticipated in 2022 with Initiation of Clinical Trial for VERVE-101 and IND-enabling Studies for ANGPTL3 Program Presentations at Upcoming Scientific Conferences to Highlight Novel Base Editing Approach and Proprietary Lipid Nanoparticle Delivery System Cash, Cash EquivalentsRHEA-AIneutral
02/23/22 6:30 AMNasdaq : VERV conferencesVerve Therapeutics to Present at the Cowen 42nd Annual Healthcare ConferenceVerve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, willRHEA-AIneutral
01/10/22 6:30 AMNasdaq : VERV clinical trialVerve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing ProgramsVERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data in Non-Human Primates Demonstrate Potential to Re-Dose or Sequentially Dose Base Editing ProgramsRHEA-AIvery positive
01/03/22 6:30 AMNasdaq : VERV conferencesVerve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceVerve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present atRHEA-AIneutral